RenovoRx (RNXT) announced that the Northwell Health Cancer Institute, NHCI, in New Hyde Park, NY is enrolling patients with locally advanced pancreatic cancer, LAPC, in the Company’s ongoing pivotal Phase III TIGeR-PaC clinical trial. NHCI joins clinical sites throughout the United States participating in the study.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RNXT:
- RenovoRx reports Q3 net loss $2.5M vs $1.4M last year
- Renovorx, Inc. (RNXT) Q3 Earnings Cheat Sheet
- RenovoRx increases production of FDA-cleared RenovoCath
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
